.

Defense Digest

Important Distinctions for the Statute of Limitations in a Medical Negligence Case in Delaware

Defense Digest, Vol. 27, No. 4, September 2021

September 1, 2021

by Lisa L. Maeyer

Key Points:

  • The phrase “injury occurred” in Delaware Code Title 18 Section 6856 means the date when the wrongful act or omission occurred, not when the claimant discovered the act.
  • The continuous negligent treatment doctrine applies in cases where there is a continuum of negligent treatment and the statute of limitations commences on the date of the last act in the negligent continuum.
  • The continuing treatment doctrine applies in cases where there was an initial act of negligent treatment but no negligence “continuum,” but is not recognized in Delaware.
  • Where the injury coincides with the negligence is when the “injury occurred.” But under the unique facts of Anderson, the injury did not arise at the time of negligence, so the Superior Court should make a factual determination regarding when the injury occurred for application of the statute of limitations.

The statute of limitations for a medical negligence case in Delaware is two years, commencing on the date of injury or, alternatively, three years, if the injury is unknown to the injured person and cannot be discovered through reasonable diligence within two years of the injury date. GI Assocs. of Del., P.A. v. Anderson, 247 A.3d 674 (Del. 2021); see also 18 Del. C. § 6856. The Delaware Supreme Court recently discussed two doctrines that inform the determination of when the statute of limitations commences: (1) the continuous negligent medical treatment doctrine; and (2) the continuing treatment doctrine. Anderson, 247 A.3d at 677.

The continuous negligent medical treatment doctrine applies in cases where there was a continuous course of improper treatment so intertwined that it would be illogical to break it up into individual acts of negligence. Ewing v. Beck, 520 A.2d 653, 662 (Del. 1987). The statute of limitations begins on the date of the last negligent act in the continuum of negligent medical care. Thus, a plaintiff is permitted to bring suit for the consequences of the entire course of negligent conduct. However, under the continuous negligent medical treatment doctrine, the plaintiff must allege there was negligence on the date they claim the statute of limitations to have commenced.

By contrast, the continuing treatment doctrine applies in cases where there was an initial act of negligent treatment but no negligence “continuum,” like under the continuous negligent medical treatment doctrine. Under the continuing treatment doctrine, the statute of limitations begins on the date of the last act of treatment related to the initial negligence, regardless of whether or not the last act itself was negligent. Whereas the continuous negligent medical treatment doctrine is limited to the last act in the negligent continuum, the continuing treatment doctrine is more flexible and reaches to the last act in the treatment. Benge v. Davis, 553 A.2d 1180, 1183 (Del. 1989) (citing Ewing, 520 A.2d at 663, n.11). Unlike under the continuous negligent medical treatment doctrine, it does not matter whether negligence continued throughout the entire course of treatment under the continuing treatment doctrine.

Delaware recognizes the continuous negligent medical treatment doctrine, but not the continuing treatment doctrine because “injury occurred” in § 6856 means the date of occurrence, not of discovery. The first Delaware case to address an equitable tolling doctrine in medical negligence cases was Layton v. Allen, 246 A.2d 794 (Del. 1968), where the court held that when an individual sustains an unknowable injury and the harmful effect develops gradually over time, the injury is “sustained” when the harmful effect first manifests itself and becomes physically ascertainable. This open-ended statute of limitations led to a medical malpractice plight, and the Delaware legislature responded by enacting Delaware Code Title 18 Section 6856. In the first case applying the language of Title 18 of Delaware Code Section 6856, Dunn v. St. Francis Hospital, Inc., 401 A.2d 77 (Del. 1979), the Delaware Supreme Court established that under the language of Delaware Code Title 18 Section 6856, “injury occurred” means the date when the wrongful act or omission occurred, not when the act was discovered.

Twenty-one years later in Meekins v. Barnes, 745 A.2d 893 (Del. 2000), the court determined that an act of omission is a valid basis for a medical malpractice claim, but only if that act of omission occurs in the context of another affirmative act, such as failing to diagnose breast cancer at a mammogram appointment. Nine years after Meekins, the court held in Dambro v. Meyer, 974 A.2d 121 (Del. 2009), that the phrase “injury occurred” in Section 6856 refers to the date when the wrongful act or omission occurred, such as the day treatment was delayed and on which a cancer diagnosis could have been made.

In the recent Anderson case, a doctor performed a colonoscopy on the late Mr. William King on April 4, 2011. At a follow-up visit on April 26, 2011, the doctor recommended that Mr. King return for his next colonoscopy in three to five years. Mr. King returned for a colonoscopy within five years—on March 26, 2016—but the colonoscopy could not be completed because a cancerous growth had formed in Mr. King’s colon. He died a few months later. A wrongful death action was filed on April 16, 2018, which claimed that the colonoscopy recommendation that had been made on April 26, 2011, was negligent. Following the doctor’s motion for summary judgment based upon the statute of limitations, the plaintiffs successfully argued that the continuous negligent medical treatment doctrine applied, and the trial court held that the statute of limitations had commenced on March 26, 2016, when the follow-up colonoscopy was performed and the injury was discovered. On appeal, however, the Delaware Supreme Court held that the continuous negligent medical treatment doctrine did not apply because the plaintiffs did not allege negligence in association with the attempted procedure on March 26, 2016.

The court further concluded that the plaintiffs claimed a single act of alleged medical negligence that occurred on April 26, 2011. Under the unique facts in Anderson, the injury did not appear to arise at the time of the alleged breach of the standard of care. Therefore, because Delaware does not recognize the continuing treatment doctrine and the facts in Anderson did not fall under the continuous negligent medical treatment doctrine, the Delaware Supreme Court reversed and remanded to the Superior Court, where the defendants are free to pursue their statute of limitations defense. The Superior Court has been instructed to factually determine the date of injury for purposes of application of the statute of limitations.

*Brad is a shareholder and the supervising attorney for Health Care Liability Group in our Wilmington, Delaware, office. He can be reached at 302.552.4328 or bjgoewert@mdwcg.com. Lisa Maeyer, a law clerk in our Wilmington office, also contributed to this article.

Defense Digest, Vol. 27, No. 4, September 2021 is prepared by Marshall Dennehey Warner Coleman & Goggin to provide information on recent legal developments of interest to our readers. This publication is not intended to provide legal advice for a specific situation or to create an attorney-client relationship. ATTORNEY ADVERTISING pursuant to New York RPC 7.1. © 2021 Marshall Dennehey Warner Coleman & Goggin. All Rights Reserved. This article may not be reprinted without the express written permission of our firm. For reprints, contact tamontemuro@mdwcg.com.

Firm Highlights

Thought Leadership

New Jersey Expands Family Leave Protections Effective July 17, 2026

On January 17, 2026, Governor Murphy signed into law legislation expanding the New Jersey Family Leave Act (NJFLA). Beginning July 17, 2026, significant amendments to the NJFLA will expand job-protected family leave to smaller businesses and more employees across the state. The new law broadens coverage by lowering the threshold for private employers from 30 employees to 15 employees, meaning many smaller businesses will now be subject to the NJFLA. Employees of state and local government agencies will continue to be covered regardless of the size of the employer. The amendments also make it easier for employees to qualify for leave. Under the revised law, an employee will be eligible after three months of employment and at least 250 hours worked during the preceding 12 months, replacing the previous requirement of 12 months of employment and 1,000 hours worked. Currently, New Jersey's Temporary Disability Insurance (TDI) and Family Leave Insurance (FLI) programs provide eligible employees with wage replacement while they are on leave but do not independently guarantee job protection. The recent amendments to the New Jersey Family Leave Act (NJFLA) expand these protections by extending job-protected leave to additional employees. Under the amended law, employees receiving TDI or FLI benefits may be entitled to return to the same position they held before taking leave, or to an equivalent position with the same seniority, status, pay, and benefits. Although the legislation also states that it does not expand or modify an employee's reinstatement rights under the NJFLA, the amendments appear to provide job protection to eligible employees receiving TDI or FLI benefits without requiring them to separately satisfy the eligibility requirements of the NJFLA or the federal Family and Medical Leave Act (FMLA). As a result, some employees may be entitled to longer periods of job-protected leave than were previously available under existing law. With these amendments, New Jersey continues to strengthen workplace protections by expanding access to job-protected family leave for eligible employees. These changes significantly expand access to job-protected family leave and may require employers to update their leave policies, employee handbooks, and HR practices. Notably, employers who were previously not required to administer NJFLA may need to amend their policies and/or create new protocols to come into compliance with the NJFLA. Failure to do so would prove costly, as the penalties for non-compliance are significant.

Thought Leadership

SIU Gets a Boost: NJ Supreme Court Affirms Insurers' Right to Litigate, Not Arbitrate, Fraud Claims

In a significant win for insurers' Special Investigation Units, the New Jersey Supreme Court clarified that statutory insurance fraud and racketeering claims may proceed in court rather than through PIP arbitration. At issue was whether insurance fraud claims brought under New Jersey's Insurance Fraud Prevention Act (IFPA) and the state's Anti-Racketeering Act (NJ RICO) are subject to mandatory arbitration under the Automobile Insurance Cost Reduction Act’s (AICRA) PIP dispute-resolution framework. Allstate had sued a network of medical practices, physicians, and related corporate entities, alleging a scheme to extract more than $1.7 million in PIP benefits through fraudulent and misleading billing. The trial court dismissed Allstate's complaint and compelled arbitration, reading AICRA's arbitration clause — which covers "any dispute regarding the recovery of... benefits" under PIP coverage, N.J.S.A. 39:6A-5.1(a) — as sweeping in fraud and racketeering claims along with routine benefit disputes. The Supreme Court affirmed the Appellate Division's reversal, adopting Judge Gilson's opinion below (480 N.J. Super. 566 (App. Div. 2025)) as its own reasoning. The Court held that IFPA and RICO claims fall outside the scope of AICRA's PIP arbitration mechanism because that "streamlined and specialized" process cannot grant the relief those statutes contemplate — treble damages, injunctive relief, broad discovery, and joinder of third parties — and because arbitrators lack authority to award compensatory or treble damages to an insurer. The Court also rejected the argument that Allstate's own Decision Point Review Plans independently compel arbitration, finding those plan provisions no broader than AICRA's own arbitration clause. Notably, the Court expressly disagreed with the Third Circuit's contrary holding in GEICO v. Mt. Prospect Chiropractic Center, 98 F.4th 463 (3d Cir. 2024), concluding it is not bound by that federal interpretation of New Jersey law. Insurers retain the right to pursue IFPA and RICO claims in the Law Division, with a jury trial. For SIU units and NJ insurance carriers, this decision is a significant win: it forecloses defense clinics' primary procedural tool for shunting fraud investigations into limited-scope PIP arbitration, where treble damages, RICO relief, and meaningful discovery were never realistically available. Carriers building cases against fraudulently structured clinics, straw-owned practices, or coordinated billing networks can now proceed with confidence that a well-pleaded IFPA/RICO complaint stays in the Law Division rather than being diverted to arbitration on a motion to compel. Practically, this strengthens SIU's leverage in settlement negotiations, preserves civil discovery tools (subpoenas, depositions, joinder of related corporate entities) critical to unwinding complex ownership and referral schemes, and resolves the split with the Third Circuit in favor of NJ insurers — at least as a matter of state law. Expect increased reliance on IFPA civil actions, rather than PIP arbitration demands, as SIU's primary enforcement vehicle going forward.

Result

No-Cause Jury Verdict Secured in Wrongful Death Trial

We successfully obtained a no-cause jury verdict in a 13-day wrongful death trial. The decedent, a 59-year-old man, was admitted to the emergency room on February 15, 2019, with complaints of abdominal pain, decreased appetite, and constipation, despite the use of laxatives. The patient did not complain of any nausea, vomiting, or diarrhea. He had a significant medical history including diabetes, hypertension, prior coronary artery stenting, morbid obesity (with past gastric bypass surgery), longstanding ventral hernia, and back pain. A CT scan revealed multiple hernias and a potential closed-loop bowel obstruction, leading to a surgery consultation. Our client, an emergency general surgeon, interpreted that the patient did not have a closed loop or any significant obstruction and recommended non-surgical management. The patient was approved to have clear liquids, and had a vomiting incident shortly after, but our client was not notified. The patient was returned to NPO status, and after improving overnight, he was returned to “clears” and additional medical and renal consults were ordered. Our client did not receive any communications from the residents/nurses of any changes in the patient’s condition. On February 18, 2019, two rapid responses were called due to increased heart rate and vomiting. It is believed that the vomiting resulted in aspiration, causing sepsis, ultimately leading to the patient’s death. During the trial, the plaintiff’s sole medical expert highlighted imaging on the wrong hernia, which called into question all of his opinions in the case. We made key objections related to the expert testimony, limiting what the allegations were, and preventing new allegations from being made. After approximately two and a half hours of deliberating, the jury returned a no-cause verdict. 

Thought Leadership

Congress Passes Financial Exploitation Prevention Act

On June 25, 2026, the House passed the Financial Exploitation Prevention Act of 2025 (“the Act”) by a vote of 414 to 2. The Act allows financial advisors and firms to delay suspicious transactions regarding the accounts of clients who are 65 or older, if they believe financial exploitation has occurred or is about to take place. With the advancement of technology and AI, the House’s overwhelming bipartisan passage of the Financial Exploitation Prevention Act represents an important step in strengthening the financial industry’s ability to combat the growing threat of elder financial exploitation. The Act recognizes what advisors have long known that financial professionals are often the first to detect suspicious behavior but have historically lacked clear legal authority to intervene before irreversible financial harm occurs. From the industry’s perspective, the bill accomplishes several important objectives, including the following: (1) Provides a practical “pause button” by allowing financial professionals to temporarily delay certain transaction requests when there is a reasonable belief that a senior or vulnerable adult is being financially exploited; (2) Empowers financial professionals to act by providing greater certainty that firms can act in good faith to protect clients without unnecessary legal risk; and (3) Strengthens investor protection without sacrificing client rights by allowing temporary delays based on a reasonable suspicion of exploitation, which is intended only to allow additional review and not to deny clients access to their money indefinitely. In sum, the Financial Exploitation Prevention Act will equip financial professionals with practical, carefully tailored tools to stop suspected financial exploitation before client assets are lost. By allowing firms to temporarily delay suspicious transactions under defined circumstances, Congress is recognizing the critical role advisors play as the first line of defense against increasingly sophisticated fraud schemes. The Act strikes an appropriate balance between protecting vulnerable investors and preserving individual financial autonomy, while reinforcing collaboration among advisors, families, and law enforcement to combat financial exploitation. The bill now awaits Senate action.